Third Phase 3 Trial of Sativex, Cannabis Extract for MS Spasticity, Planned

Third Phase 3 Trial of Sativex, Cannabis Extract for MS Spasticity, Planned

302322

Third Phase 3 Trial of Sativex, Cannabis Extract for MS Spasticity, Planned

Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to initiate this year, the RELEASE MSS5 trial (NCT04984278) is expected to enroll about 190 adults with any type of MS and spasticity (muscle stiffness and spasms). While study sites are yet to be announced, contact information is…

You must be logged in to read/download the full post.